Zhang Eric 4
4 · Aravive, Inc. · Filed Oct 16, 2018
Insider Transaction Report
Form 4
Aravive, Inc.ARAV
Zhang Eric
Director
Transactions
- Award
Common Stock
2018-10-12+859,766→ 859,766 total(indirect: See footnote)
Footnotes (2)
- [F1]Shares of common stock of the corporation known as Aravive Biologics, Inc. ("Aravive") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of June 3, 2018, by and among the Issuer, Velo Merger Sub, Inc. and Aravive (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of Aravive common stock was exchanged for 2.2801 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one share for every six shares of Issuer common stock and the Issuer changed its name to Aravive, Inc. All share numbers reflect the reverse stock split.
- [F2]Shares of common stock of the Issuer held by Elite Vantage Global Limited. The Reporting Person is a director of Elite Vantage Global Limited. The address for Elite Vantage Global Limited is Suite 1807, 18F, China Resources Building, 26 Harbor Road, Hong Kong. The Reporting Person disclaims beneficial ownership of the shares held by Elite Vantage Global Limited except to the extent of his pecuniary interest therein.